Classification criteria have been developed by the scientific community to improve communication and facilitate clinical studies. In clinical practice, however, it is not unusual to come across systemic autoimmune diseases that do not meet the existing classification criteria. These diseases have been variously termed as incomplete lupus erythematosus, undifferentiated connective tissue diseases (UCTD) or undifferentiated connective tissue syndromes. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] However, a review of the literature shows that a broad range of conditions including transitory diseases, the initial phases of defined CTD, incomplete forms of defined CTD, and conditions that cannot be classified or diagnosed based on the clinical findings have been classified as UCTD. 4, 9, 15, [19] [20] [21] [22] [23] [24] Studies demonstrate that a certain proportion of UCTD patients will eventually develop defined CTD, generally systemic lupus erythematosus (SLE), but others develop conditions such as systemic sclerosis (SSc), Sjögren's syndrome, mixed connective tissue diseases, rheumatoid arthritis (RA), systemic vasculitis and polydermatomyositis. [2] [3] [4] [6] [7] [8] [9] [11] [12] [13] [14] [15] The marked discrepancy in the reported rates of such an evolution -ranging from 10% to 70% -may be attributable to the characteristics of the patients recruited in different studies, in particular their disease duration. Higher incidences have been reported during the first 3-5 years of the disease, and, therefore, studies that include patients with recent onset UCTD are likely to see a larger number evolving to a CTD. In contrast, UCTD of long duration is much less likely to develop into a defined CTD.
At the same time, a distinct subgroup of patients can be identified who will maintain an undefined profile during follow-up. 4, [6] [7] [8] [11] [12] [13] [14] [15] Their disease can be termed stable UCTD, a condition with low disease activity, a low incidence of flares (7% in our patient population over 1 year; unpublished data) and the absence of severe organ involvement (e.g. pulmonary fibrosis, kidney or neurological impairment). The most common clinical manifestations are non-erosive arthritis; Raynaud's phenomenon without swollen hands, sclerodactily or nailfold capillaroscopic abnormalities suggestive of SSc; sicca symptoms (but negative salivary gland biopsy and ocular test results) and leucopenia. The serological profile is positive for antinuclear antibodies (ANA), generally with a single autoantibody specificity (anti-Ro/SSA or anti-RNP) and only rarely disease-specific autoantibodies (usually antidsDNA antibodies). [5] [6] [7] 10, 11, [13] [14] [15] 18 Because it is a mild condition, in most clinical studies stable UCTD has been treated with low-dose corticosteroids (CS) and/or antimalarial drugs, with a notable percentage (20-40%) not requiring any treatment during follow-up. 6, 12, 14 In a cohort of 152 stable UCTD patients who have been followed for more than 10 years at our clinic, 16% were not on any therapy at their last check-up; of the remainder, 36% were being treated with hydroxychloroquine (HCQ), 26% with HCQ and CS, 10% with CS alone, and no patient was receiving immunosuppressive (IS) drugs (personal data).
These data suggest that the stable UCTD constitute distinct clinical entities. As they are relatively uncomplicated conditions, they could provide a model for the study of systemic autoimmune diseases, the pathogenetic role of autoantibodies, and the correlation between systemic autoimmune diseases and other diseases (e.g. accelerated atherosclerosis).
Stable UCTD: a systemic autoimmune disease model
It is known that pregnancy can affect the course of many systemic autoimmune diseases; for instance, patients with CTD appear to suffer more frequently from obstetric complications than the general population of pregnant women. As part of an ongoing study, we have been analysing the pregnancy outcome in stable UCTD, and preliminary results from a series of 25 pregnancies followed in 20 patients show that many of them experienced an increase in flares during their pregnancy (24% versus 7% in non-pregnant patients). The occurrence of obstetrical complications was also higher than the expected rate for the general population. 17 Accelerated atherosclerosis and cardiovascular disease (CVD) are seen in many systemic autoimmune diseases including SLE, RA and systemic vasculitis. Variables directly linked to systemic autoimmunity (chronic inflammation, autoantibodies, etc.) could contribute to the development of CVD, but it is difficult to study their role in the CTD due to the presence of confounding factors such as therapy, the type and severity of organ involvement and the development of damage. 25 The stable UCTD could instead represent viable models for the study of premature atherosclerosis and CVD. We have been assessing endothelial function in patients with stable UCTD compared with SLE patients and healthy controls and -most interestingly -observed an impaired, endothelium-dependent response in UCTD patients similar to that reported in SLE patients. Further studies are being conducted to correlate the presence of endothelial dysfunction with specific autoantibodies and disease manifestations.
If researchers are to exploit this model, however, they need the tools to reliably diagnose patients with stable UCTD. Identifying clusters of clinically related diseases could pave the way for the study of the pathogenetic mechanisms of autoimmune conditions in both observational studies and randomized controlled trials. Being able to distinguish mild conditions from more severe disease (in both its full-blown and incomplete forms) could also lessen the psychological burden of the disease, reduce the risk of over-treatment and lower the economic cost of these diseases to the community.
How to distinguish stable UCTD from incomplete CTD and the initial phases of defined CTD?
In 1999, we proposed a preliminary set of classification criteria for the identification of UCTD: (i) signs and symptoms suggestive of a CTD, but not sufficient to meet the criteria for a defined CTD; (ii) positive ANA and (iii) a disease duration of at least 3 years. We suggested adopting the term 'early UCTD' to refer the conditions with a disease duration of <3 years. 10 This criterion would allow the exclusion of transitory conditions and the early forms of defined CTD which, as noted above, tend to emerge between the third and fifth year of the disease course. In addition, the criterion of a positive ANA would help to exclude early arthritis and the seronegative arthritides. However, these criteria still do not allow us to identify a UCTD at its very onset, and they do not exclude the incomplete forms of defined CTD.
This problem might be resolved by the addition of exclusion criteria applicable to the patients at disease onset. In 2005, we proposed a tentative set of exclusion criteria (Table 1) , 26 but these need to be confirmed and refined based on a careful review of the literature and studies involving large and homogeneous cohorts of patients.
Conclusions
Published data suggests that there is a group of systemic autoimmune diseases that can be neither classified using present criteria nor diagnosed on the basis of the patient's clinical manifestations. Such conditions, which are characterized by a mild clinical picture, a simple serological profile and do not change over time, have been termed as stable UCTD.
The stable UCTD can be regarded as distinct systemic autoimmune diseases, and given their simple profile, they could serve as models for the study of autoimmune diseases in general. However, the diagnosis of stable UCTD requires the exclusion of the incomplete forms and the early phases of defined CTD. The definition of inclusion and exclusion criteria for the classification of stable UCTD would help us to reach this goal. 
